Clinical Trial Update: Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) [Phase 2, Phase 3]

View source ↗

Summary

This update reports results from a Phase 2/Phase 3 study of Imetelstat (GRN163L) in participants with IPSS low- or intermediate-1 risk myelodysplastic syndrome.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Imetelstat (imetelstat)

Snippet

Sponsor: Geron Corporation | Conditions: Myelodysplastic Syndromes | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-02-14